- Home
- DXR vs HOWL Comparison
DXR vs HOWL Comparison
Compare DXR & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | HOWL |
|---|---|---|
| Founded | 1970 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 64.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DXR | HOWL |
|---|---|---|
| Price | $12.80 | $0.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $25.00 | $7.00 |
| AVG Volume (30 Days) | 7.4K | ★ 553.7K |
| Earning Date | 02-27-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.46 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $66,306.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.55 | $0.53 |
| 52 Week High | $14.76 | $2.38 |
Technical Indicators
Market Signals| Indicator | DXR | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 52.97 |
| Support Level | $11.87 | $0.63 |
| Resistance Level | $12.90 | $0.74 |
| Average True Range (ATR) | 0.63 | 0.06 |
| MACD | -0.22 | 0.03 |
| Stochastic Oscillator | 12.00 | 69.17 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.